Development of a new estrogen replacement therapy based on a central action of a menopausal metabolic disorder and depression

The depression and the anxiety increased for menopaused women associated with an estrogen (E2) decline. These E2 decline is related to overweight and diabetes, and the improvement effect of the peripheral administration of E2 is reported. But systemic estrogen replacement therapy has a risk for breast cancer and a cardiovascular disease. So we elucidated depression and anxiety improvement effect by central selective E2 administration, drafted a study for the purpose of development of the central selective hormone replacement therapy which evaded a complication and got the following result. 1) The E2 central administration (E2-ICV) improved obesity, impaired glucose tolerance to detect in menopaused obese mice (OVX-HF). 2) E2-ICV improved depressive state by a tail suspension test in OVX-HF. 3) E2-ICV was improved anxiety state by the evaluation of an open field test in OVX-HF.